NASDAQ:AMRS - Amyris Stock Price, Forecast & News

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Shares of Amyris reverse split on the morning of Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris Inc (NASDAQ:AMRS) posted its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.02. The biotechnology company had revenue of $34.95 million for the quarter, compared to analyst estimates of $21.60 million. View Amyris' Earnings History.

Amyris is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Amyris.

Amyris updated its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $$150 million, compared to the consensus revenue estimate of $$148.65 million.

2 Wall Street analysts have issued 1 year target prices for Amyris' stock. Their forecasts range from $8.00 to $11.00. On average, they anticipate Amyris' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 187.9% from the stock's current price. View Analyst Price Targets for Amyris.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

News stories about AMRS stock have been trending negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Amyris earned a daily sentiment score of -2.2 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Amyris.

Amyris saw a increase in short interest in January. As of January 31st, there was short interest totalling 19,160,000 shares, an increase of 11.5% from the January 15th total of 17,190,000 shares. Based on an average daily trading volume, of 1,180,000 shares, the days-to-cover ratio is presently 16.2 days. Approximately 38.5% of the shares of the stock are short sold. View Amyris' Current Options Chain.

Some companies that are related to Amyris include Phillips 66 (PSX), Marathon Petroleum (MPC), Valero Energy (VLO), HollyFrontier (HFC), CVR Energy (CVI), PBF Energy (PBF), World Fuel Services (INT), Delek US (DK), Renewable Energy Group (REGI), Clean Energy Fuels (CLNE), REX American Resources (REX), Green Plains (GPRE), Adams Resources & Energy (AE) and Gevo (GEVO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Canopy Growth (CGC), Advanced Micro Devices (AMD), Intel (INTC), MEI Pharma (MEIP), General Electric (GE) and Amarin (AMRN).

Amyris' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (8.01%), Pinnacle Associates Ltd. (1.29%), State Street Corp (0.83%), Geode Capital Management LLC (0.65%), Essex Investment Management Co. LLC (0.42%) and Goldman Sachs Group Inc. (0.29%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris.

AMRS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Goldman Sachs Group Inc., Principal Financial Group Inc., Alliancebernstein L.P., Bank of America Corp DE and Rice Hall James & Associates LLC. Company insiders that have sold Amyris company stock in the last year include John Melo and Patrick Y Yang. View Insider Buying and Selling for Amyris.

AMRS stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Pinnacle Associates Ltd., Essex Investment Management Co. LLC, State Street Corp, Geode Capital Management LLC, Spark Investment Management LLC, Virtus ETF Advisers LLC and Levin Capital Strategies L.P.. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Insider Buying and Selling for Amyris.

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMRS stock can currently be purchased for approximately $3.30.

Amyris has a market capitalization of $348.15 million and generates $80.42 million in revenue each year. The biotechnology company earns $-230,240,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. Amyris employs 414 workers across the globe.View Additional Information About Amyris.

The official website for Amyris is http://amyris.com/.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]